Metabolism of borono-phenylalanine-fructose complex (BPA-fr) and borocaptate sodium (BSH) in cancer patients--results from EORTC trial 11001.
Peter Bendel, Andrea Wittig, Fabrizio Basilico, Pier Luigi Mauri, Wolfgang Sauerwein
Index: J. Pharm. Biomed. Anal. 51(1) , 284-7, (2010)
Full Text: HTML
Abstract
Within the clinical trial EORTC 11001, patients were infused with (10)B-enriched borono-phenylalanine-fructose complex (BPA-fr), or borocaptate sodium (BSH) solutions, which are used as boron carriers for boron neutron capture therapy. Urine samples were periodically collected and analyzed by (10)B NMR spectroscopy. The results revealed time-dependent metabolic changes of the administered compounds. BPA-fr dissociated to the constituents BPA and fructose, and the borate group was partly cleaved from BPA. BSH was partly aggregated to a dimer form, BSSB. These observations were previously reported for cultured cells and animal models, and are confirmed here in human cancer patients.
Related Compounds
Related Articles:
2014-04-01
[J. Nucl. Med. 55(4) , 616-21, (2014)]
2011-12-01
[Appl. Radiat. Isot. 69(12) , 1728-31, (2011)]
Boron neutron capture therapy induces apoptosis of glioma cells through Bcl-2/Bax.
2010-01-01
[BMC Cancer 10 , 661, (2010)]
2011-12-01
[Appl. Radiat. Isot. 69(12) , 1752-5, (2011)]
2011-12-01
[Appl. Radiat. Isot. 69(12) , 1721-4, (2011)]